poisar

Stock

MIRA Pharmaceuticals, Inc. MIRA

$0.87-6.79%

Overview

MIRA market data

Price History

MIRA price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.44
Diluted earnings per share over the trailing twelve months.
Beta
1.65
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.89 – $2.45
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $38.9 · P/B 6.09.

Company news

10 captured
MIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory PainBenzinga · Jul 10, 2026, 12:10 PM
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)SEC EDGAR · Jul 10, 2026, 12:00 PM
MIRA Pharmaceuticals Reports Data From Its SKNY-1 Oral Formulation To Treat Obesity, Addiction-Related DisordersBenzinga · Jul 6, 2026, 1:10 PM
MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain ReliefBenzinga · Jun 25, 2026, 12:25 PM
MIRA Pharmaceuticals Files Phase 2a Clinical Study Protocol To FDA For Ketamir-2 Oral NMDA Receptor ModulatorBenzinga · Jun 17, 2026, 12:10 PM
Mira Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026Benzinga · Jun 8, 2026, 9:10 PM
MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1Benzinga · Jun 4, 2026, 12:05 PM
MIRA Pharmaceuticals Executes Amendment To Its Exclusive Ketamir-2 License Agreement With MIRALOGX To Expand Licensed TerritoryBenzinga · May 27, 2026, 12:03 PM
MIRA Pharma Announces Unblinded Results From Completed Phase 1 Clinical Trial Evaluating Ketamir-2, Proprietary Selective Oral NMDA Receptor ModulatorBenzinga · May 14, 2026, 12:10 PM
MIRA Pharmaceuticals Announces Acceptance And Publication Of A Peer-Reviewed Manuscript On SKNY-1 In The International Journal Of Molecular SciencesBenzinga · May 13, 2026, 12:09 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock